echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Merck halts two clinical trials of anti-AIDS drug islatravir

    Merck halts two clinical trials of anti-AIDS drug islatravir

    • Last Update: 2021-12-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    CompilationAspirin

    Merck is currently developing islatravir, an anti-AIDS drug candidate that is taken orally once a month


    On December 6, 2021, Eastern Time, Merck announced that it will suspend patient recruitment for two Phase III trials for the evaluation of this drug


    This decision is based on the recommendation of the external data monitoring committee (eDMC) of islatravir pre-exposure prevention (PrEP) that Merck suspends the recruitment of IMPOWER 22 and IMPOWER 24 clinical trials in order to facilitate the company’s evaluation of these studies.


    Regarding the suspension of this anti-AIDS drug by Merck, investors said it was not unexpected


    Earlier last month, Merck stopped a Phase II clinical study called IMAGINE-DR, which raised the alarm for the safety of the drug for the first time


    Another unfortunate news in the field of anti-AIDS drug research is that the pharmaceutical giant and Merck’s anti-AIDS partner Gilead also stated that out of caution, they suspended patient recruitment for a separate study that used Merck An investigational drug in a separate trial


    Islatravir is one of the two core drugs of long-acting anti-HIV therapy jointly developed by Merck and Gilead.


    Reference source: Merck pumps the brakes on two more PhIII trials for its lead anti-HIV drug

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.